| Source: |
| Type: |
| Gut microbiome may affect responses to numerous forms of cancer therapy. The gut microbiota plays a multifaceted role in cancer biology, influencing tumor development, progression, and patient prognosis. Dysbiosis and specific microbial populations have been linked to various cancers, with implications for patient outcomes. While the relationship between gut microbiota and cancer prognosis is an active area of research, it holds promise for the development of microbiome-based biomarkers and therapeutic strategies in oncology. |
| Colon cancer can start anywhere in the colon, (5 feet long) and absorbs water from stool. Rectal cancer starts in the rectum, which is the last 12 centimeters. |
| 1161- | ACNs, | immuno, | Bilberry anthocyanin extracts enhance anti-PD-L1 efficiency by modulating gut microbiota |
| - | in-vivo, | Colon, | MC38 |
| 2712- | BBR, | Suppression of colon cancer growth by berberine mediated by the intestinal microbiota and the suppression of DNA methyltransferases (DNMTs) |
| - | in-vitro, | Colon, | HT29 | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:31 Cells:% prod#:% Target#:350 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid